{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:19:28Z","timestamp":1786760368909,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02540-7","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:55:00Z","timestamp":1740488100000},"page":"810-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia"],"prefix":"10.1038","volume":"39","author":[{"given":"Xiaowen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-4931","authenticated-orcid":false,"given":"Junren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2540_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2540_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J"},{"key":"2540_CR3","unstructured":"NCCN Guidelines: chronic myeloid leukemia. Version 3. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf."},{"key":"2540_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267\u201370.","journal-title":"Nature"},{"key":"2540_CR5","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1634\/stemcells.2006-0136","volume":"24","author":"D Dingli","year":"2006","unstructured":"Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells. 2006;24:2603\u201310.","journal-title":"Stem Cells"},{"key":"2540_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12:1181\u20134.","journal-title":"Nat Med"},{"key":"2540_CR7","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","volume":"118","author":"M Tang","year":"2011","unstructured":"Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011;118:1622\u201331.","journal-title":"Blood"},{"key":"2540_CR8","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Iniguez A, Jena N, Tata P, Liu ZY, Lander AD, et al. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy. Elife. 2023;12:e84149.","DOI":"10.7554\/eLife.84149"},{"key":"2540_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","volume":"121","author":"M Horn","year":"2013","unstructured":"Horn M, Glauche I, Muller MC, Hehlmann R, Hochhaus A, Loeffler M, et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood. 2013;121:378\u201384.","journal-title":"Blood"},{"key":"2540_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29923-4","volume":"8","author":"I Glauche","year":"2018","unstructured":"Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, et al. Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison. Sci Rep. 2018;8:12330.","journal-title":"Sci Rep."},{"key":"2540_CR11","first-page":"2893","volume":"109","author":"S Saugues","year":"2024","unstructured":"Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, et al. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort. Haematologica. 2024;109:2893\u2013907.","journal-title":"Haematologica"},{"key":"2540_CR12","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196\u2013207.","journal-title":"Blood"},{"key":"2540_CR13","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u2013535.","journal-title":"Lancet Haematol"},{"key":"2540_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"2540_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846\u201354.","journal-title":"Blood"},{"key":"2540_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"2540_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"2540_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"2540_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018;168:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2540_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109:182\u201392.","journal-title":"Cancer Sci"},{"key":"2540_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017;35:298\u2013305.","journal-title":"J Clin Oncol"},{"key":"2540_CR22","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clin Cancer Res. 2019;25:6606\u201313.","journal-title":"Clin Cancer Res"},{"key":"2540_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0125-0","volume":"8","author":"JC Hernandez-Boluda","year":"2018","unstructured":"Hernandez-Boluda JC, Pereira A, Pastor-Galan I, Alvarez-Larran A, Savchuk A, Puerta JM, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018;8:91.","journal-title":"Blood Cancer J"},{"key":"2540_CR24","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"2540_CR25","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1001\/dmp.2011.21","volume":"5","author":"EB Douple","year":"2011","unstructured":"Douple EB, Mabuchi K, Cullings HM, Preston DL, Kodama K, Shimizu Y, et al. Long-term radiation-related health effects in a unique human population: lessons learned from the atomic bomb survivors of Hiroshima and Nagasaki. Disaster Med Public Health Prep. 2011;5:S122\u201333.","journal-title":"Disaster Med Public Health Prep"},{"key":"2540_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1667\/RR2892.1","volume":"179","author":"WL Hsu","year":"2013","unstructured":"Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013;179:361\u201382.","journal-title":"Radiat Res"},{"key":"2540_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000204364","volume":"90","author":"I Aurer","year":"1993","unstructured":"Aurer I, Juhbashi T, Sekine I, Tomonaga M, Gale RP. Analysis of BCR\/ABL abnormalities in mRNA from 20-year-old paraffin-embedded tissue for BCR\/ABL rearrangement by polymerase chain reaction. Acta Haematol. 1993;90:5\u20137.","journal-title":"Acta Haematol"},{"key":"2540_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00411-013-0507-4","volume":"53","author":"T Radivoyevitch","year":"2014","unstructured":"Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014;53:55\u201363.","journal-title":"Radiat Environ Biophys"},{"key":"2540_CR29","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s41375-020-0957-z","volume":"34","author":"M Abecasis","year":"2020","unstructured":"Abecasis M, Cross NCP, Brito M, Ferreira I, Sakamoto KM, Hijiya N, et al. Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. Leukemia. 2020;34:2279\u201384.","journal-title":"Leukemia"},{"key":"2540_CR30","doi-asserted-by":"publisher","first-page":"e28706","DOI":"10.1002\/pbc.28706","volume":"68","author":"A Meral Gunes","year":"2021","unstructured":"Meral Gunes A, Millot F, Kalwak K, Lausen B, Sedlacek P, Versluys AB, et al. Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry. Pediatr Blood Cancer. 2021;68:e28706.","journal-title":"Pediatr Blood Cancer"},{"key":"2540_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2018.00194","volume":"8","author":"M Bocchia","year":"2018","unstructured":"Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, et al. Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Front Oncol. 2018;8:194.","journal-title":"Front Oncol"},{"key":"2540_CR32","doi-asserted-by":"crossref","unstructured":"Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, et al. Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). Cancers. 2023;15:4112.","DOI":"10.3390\/cancers15164112"},{"key":"2540_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41375-023-02124-3","volume":"38","author":"M Pfirrmann","year":"2024","unstructured":"Pfirrmann M, Saussele S, Mahon FX, Richter J. How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia. 2024;38:460\u20132.","journal-title":"Leukemia"},{"key":"2540_CR34","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3324\/haematol.2018.214809","volume":"104","author":"S Claudiani","year":"2019","unstructured":"Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, et al. MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica. 2019;104:2206\u201314.","journal-title":"Haematologica"},{"key":"2540_CR35","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u2013e383.","journal-title":"Lancet Haematol"},{"key":"2540_CR36","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123:4403\u201310.","journal-title":"Cancer"},{"key":"2540_CR37","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/bjh.18796","volume":"201","author":"S Dulucq","year":"2023","unstructured":"Dulucq S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, et al. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study. Br J Haematol. 2023;201:1116\u201324.","journal-title":"Br J Haematol"},{"key":"2540_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41375-024-02145-6","volume":"38","author":"H Flygt","year":"2024","unstructured":"Flygt H, Soderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia. 2024;38:781\u20137.","journal-title":"Leukemia"},{"key":"2540_CR39","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019;33:2358\u201364.","journal-title":"Leukemia"},{"key":"2540_CR40","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","volume":"102","author":"S Claudiani","year":"2017","unstructured":"Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, et al. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica. 2017;102:e297\u2013e299.","journal-title":"Haematologica"},{"key":"2540_CR41","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/cncr.31977","volume":"125","author":"M D\u2019Adda","year":"2019","unstructured":"D\u2019Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer. 2019;125:1674\u201382.","journal-title":"Cancer"},{"key":"2540_CR42","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"2540_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Schutz","year":"2017","unstructured":"Schutz C, Inselmann S, Saussele S, Dietz CT, Mu Ller MC, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829\u201336.","journal-title":"Leukemia"},{"key":"2540_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.16718","volume":"191","author":"YD Irani","year":"2020","unstructured":"Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191:433\u201341.","journal-title":"Br J Haematol"},{"key":"2540_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-023-01440-6","volume":"16","author":"C Pavlovsky","year":"2023","unstructured":"Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, et al. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal. J Hematol Oncol. 2023;16:43.","journal-title":"J Hematol Oncol"},{"key":"2540_CR46","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/blood-2024-201881","volume":"144","author":"CH Kok","year":"2024","unstructured":"Kok CH, Saunders VA, Shanmuganathan N, Liu L, Irani YD, Clarson J, et al. Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia. Blood. 2024;144:993.","journal-title":"Blood"},{"key":"2540_CR47","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","volume":"28","author":"JM Goldman","year":"2010","unstructured":"Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888\u201395.","journal-title":"J Clin Oncol"},{"key":"2540_CR48","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1002\/cncr.28043","volume":"119","author":"EC Hall","year":"2013","unstructured":"Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119:2300\u20138.","journal-title":"Cancer"},{"key":"2540_CR49","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.leukres.2012.07.012","volume":"36","author":"M Patel","year":"2012","unstructured":"Patel M, Philip V, Fazel F, Lakha A, Vorog A, Ali N, et al. Human immunodeficiency virus infection and chronic myeloid leukemia. Leuk Res. 2012;36:1334\u20138.","journal-title":"Leuk Res"},{"key":"2540_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.leukres.2017.03.003","volume":"57","author":"RP Gale","year":"2017","unstructured":"Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leuk Res. 2017;57:109\u201311.","journal-title":"Leuk Res"},{"key":"2540_CR51","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s11606-021-06776-8","volume":"37","author":"AS Begin","year":"2022","unstructured":"Begin AS, Hidrue M, Lehrhoff S. Del Carmen MG, Armstrong K, Wasfy JH. Factors Associated with Physician Tolerance of Uncertainty: an Observational Study. J Gen Intern Med. 2022;37:1415\u201321.","journal-title":"J Gen Intern Med"},{"key":"2540_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.31887\/DCNS.2012.14.1\/jmarewski","volume":"14","author":"JN Marewski","year":"2012","unstructured":"Marewski JN, Gigerenzer G. Heuristic decision making in medicine. Dialogues Clin Neurosci. 2012;14:77\u201389.","journal-title":"Dialogues Clin Neurosci"},{"key":"2540_CR53","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41409-020-01167-9","volume":"56","author":"RP Gale","year":"2021","unstructured":"Gale RP. Being certain even when you\u2019re wrong: heuristics and thin slicing in haematopoietic cell transplantation. Bone Marrow Transplant. 2021;56:1223\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2540_CR54","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1126\/science.abc9818","volume":"374","author":"M Singh","year":"2021","unstructured":"Singh M. Heuristics in the delivery room. Science. 2021;374:324\u20139.","journal-title":"Science"},{"key":"2540_CR55","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2540_CR56","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood.V118.21.2770.2770","volume":"118","author":"R Latagliata","year":"2011","unstructured":"Latagliata R, Breccia M, Ferrero D, Cavazzini F, Trawinska MM, Castagnetti F, et al. Imatinib in Very Elderly (>75 years) CML Patients: Are Low-Doses (<400\u2009mg daily) Enough? Blood. 2011;118:2770.","journal-title":"Blood"},{"key":"2540_CR57","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood.V122.21.4039.4039","volume":"122","author":"Y-W Won","year":"2013","unstructured":"Won Y-W, Kim D, Lee S-E, Choi SY, Kim S-H, Jang E-J. Safety and Efficacy Of Imatinib In Elderly Patients With Chronic-Phase Chronic Myeloid Leukemia: Analysis Of Outcome For < 60 Years Versus \u2265 60 Years. Blood. 2013;122:4039.","journal-title":"Blood"},{"key":"2540_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2540_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2020-140835","volume":"136","author":"E Szczepanek","year":"2020","unstructured":"Szczepanek E, Chukwu O, Kaminska M, Wysoglad H, Cenda A, Waclaw J, et al. Long-Term Outcomes of Imatinib Real-Life Treatment for Chronic Myeloid Leukemia- a 20-Year Review. Blood. 2020;136:52\u201353.","journal-title":"Blood"},{"key":"2540_CR60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.clml.2021.04.005","volume":"21","author":"AE Eskazan","year":"2021","unstructured":"Eskazan AE, Ozmen D, Oztas M, Bektas F, Bayraktar EA, Sadri S, et al. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2021;21:549\u201357.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2540_CR61","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","volume":"38","author":"S Claudiani","year":"2024","unstructured":"Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia. 2024;38:796\u2013802.","journal-title":"Leukemia"},{"key":"2540_CR62","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"2540_CR63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","volume":"193","author":"S Claudiani","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193:346\u201355.","journal-title":"Br J Haematol"},{"key":"2540_CR64","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","volume":"8","author":"K Murai","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8:e902\u2013e911.","journal-title":"Lancet Haematol"},{"key":"2540_CR65","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50\u2009mg\/day versus standard-dose dasatinib 100\u2009mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97:1413\u20138.","journal-title":"Am J Hematol"},{"key":"2540_CR66","doi-asserted-by":"crossref","unstructured":"Li Z, Zhang X, Zhao Y, Lu L, Guo Y, Gale RP, et al. Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia. Cancer. 2025;131:e35565.","DOI":"10.1002\/cncr.35565"},{"key":"2540_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.17111","volume":"192","author":"DM Ross","year":"2021","unstructured":"Ross DM, Hughes TP. Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. Br J Haematol. 2021;192:24\u201327.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02540-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:42:23Z","timestamp":1744216943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02540-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2540"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02540-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}